Download or read book Science Lessons written by Gordon M. Binder and published by Harvard Business Review Press. This book was released on 2008 with total page 326 pages. Available in PDF, EPUB and Kindle. Book excerpt: Under Gordon Binder's leadership, Amgen became the world's largest and most successful biotech company in the world. This text describes what it really takes to manage risk, financing, creative employees, and intellectual property on the international stage.
Download or read book The Amgen Story written by Amgen Inc. (Thousand Oaks, Calif.) and published by . This book was released on 2005 with total page 232 pages. Available in PDF, EPUB and Kindle. Book excerpt: As the most successful biotech company in history and the eighth largest drug-producing company in the world, Amgen has improved the lives of millions of patients worldwide. In 2005, the company celebrates its twenty-fifth anniversary with the publication of "The Amgen Story. This stunning illustrated book contains hundreds of archival photos and compelling text from noted biotech writer David Ewing Duncan. It is testament and tribute to the staff, leaders, patients, and science that make each discovery possible.
Download or read book Amgen Inc V Kidney Center of Delaware County Ltd written by and published by . This book was released on 1995 with total page 58 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Amgen written by Tim Calkins and published by . This book was released on 2017 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: In March 2015, Amgen is preparing for the launch of Repatha, a new molecule that has demonstrated a remarkable ability to treat high cholesterol. Through a series of clinical trials, Amgen has proven that the molecule is both safe and effective for patients with high cholesterol. It also is effective for patients with familial hypercholesterolemia, a difficult-to-treat population that has exceptionally high levels of cholesterol. Amgen expects the FDA to approve the molecule before the end of the year. Now, the Repatha team has to develop a revenue forecast.
Download or read book Amgen written by Gordon M. Binder and published by . This book was released on 1998 with total page 36 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Amgen Inc written by James D. Berkley and published by . This book was released on 1992 with total page 19 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Biosimilars written by Hiten J. Gutka and published by Springer. This book was released on 2018-12-13 with total page 709 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a comprehensive overview of the biosimilar regulatory framework, the development process and clinical aspects for development of biosimilars. The development path of a biosimilar is just as unique as a development path of a new drug, tailored by the mechanism of action, the quality of the molecule, published information on the reference product, the current competitive environment, the target market and regulatory guidance, and most importantly, the emerging totality of evidence for the proposed biosimilar during development. For the ease of readers, the book comprises of six sections as follows: Section I: Business, Health Economics and Intellectual Property Landscape for Biosimilars Section II: Regulatory Aspects of Development and Approval for Biosimilars Section III: Biopharmaceutical Development and Manufacturing of Biosimilars Section IV: Analytical Similarity Considerations for Biosimilars Section V: Clinical aspects of Biosimilar Development Section VI: Biosimilars- Global Development and Clinical Experience Chapters have been written by one or more experts from academia, industry or regulatory agencies who have been involved with one or more aspects of biosimilar product development. The authors and editors have an expertise in commercialization and pricing of biosimilars, intellectual property considerations for biosimilars, chemistry manufacturing controls (CMC) and analytical development for biosimilars, regulatory and clinical aspects of biosimilar development. Besides the industry practitioners, the book includes several contributions from regulators across the globe.
Download or read book The Cheating Cell written by Athena Aktipis and published by Princeton University Press. This book was released on 2020-03-24 with total page 256 pages. Available in PDF, EPUB and Kindle. Book excerpt: A fundamental and groundbreaking reassessment of how we view and manage cancer When we think of the forces driving cancer, we don’t necessarily think of evolution. But evolution and cancer are closely linked because the historical processes that created life also created cancer. The Cheating Cell delves into this extraordinary relationship, and shows that by understanding cancer’s evolutionary origins, researchers can come up with more effective, revolutionary treatments. Athena Aktipis goes back billions of years to explore when unicellular forms became multicellular organisms. Within these bodies of cooperating cells, cheating ones arose, overusing resources and replicating out of control, giving rise to cancer. Aktipis illustrates how evolution has paved the way for cancer’s ubiquity, and why it will exist as long as multicellular life does. Even so, she argues, this doesn’t mean we should give up on treating cancer—in fact, evolutionary approaches offer new and promising options for the disease’s prevention and treatments that aim at long-term management rather than simple eradication. Looking across species—from sponges and cacti to dogs and elephants—we are discovering new mechanisms of tumor suppression and the many ways that multicellular life-forms have evolved to keep cancer under control. By accepting that cancer is a part of our biological past, present, and future—and that we cannot win a war against evolution—treatments can become smarter, more strategic, and more humane. Unifying the latest research from biology, ecology, medicine, and social science, The Cheating Cell challenges us to rethink cancer’s fundamental nature and our relationship to it.
Download or read book Biologics and Biosimilars written by Xiaodong Feng and published by CRC Press. This book was released on 2022-06-13 with total page 642 pages. Available in PDF, EPUB and Kindle. Book excerpt: Biologics and Biosimilars: Drug Discovery and Clinical Applications is a systematic integration and evaluation of all aspects of biologics and biosimilars, encompassing research and development, clinical use, global regulation, and more. Biosimilars are biological therapeutic agents designed to imitate a reference biologic with high similarities in structure, efficacy, and safety, but also with potential clinical effective and cost-efficient options for the manufacturers, payers, clinicians, and patients. Most of the top-selling prescription drugs in the current market are biologics, which have revolutionized the treatment strategies and modalities for life-threatening and/or rare diseases. This book outlines the key processes and challenges in drug development, regulations, and clinical applications of biologics, biosimilars, and even interchangeable biosimilars. Global experts in the field discuss essential categories and prototype drugs of biologics and biosimilars in clinical practice such as allergenics, blood and blood components, cell treatment, gene therapy, recombinant therapeutic proteins or peptides, tissues, and vaccines. Additional features: Integrates the latest bench and bedside evidence of drug development and regulations of biologics and biosimilars Contains key study questions for each chapter to guide the readers, as well as drug charts for all therapeutic applications of biologics and biosimilars Presents detailed schematic illustrations to explain the drug development, clinical trials, regulations, and clinical applications of biologics and biosimilars This book is an invaluable tool for health care professional students, providers, and pharmaceutical and health care industries, as well as the public, providing readers with educational updates about the drug development and clinical affairs of biological medications and their similar drugs.
Download or read book Reply Brief for Amgen Inc And Amgen Manufacturing Limited written by and published by . This book was released on with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Amgen Inc s Epogen Commercializing the First Biotech Blockbuster Drug written by Dennis Yao and published by . This book was released on 2005 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book A Case Study of Amgen Inc written by James B. Neher and published by . This book was released on with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Business Statistics on the Web written by Paula Berinstein and published by Information Today, Inc.. This book was released on 2003 with total page 284 pages. Available in PDF, EPUB and Kindle. Book excerpt: This practical guide shows researchers how to tap the Internet for statistics about companies, markets, and industries; how to organize and present statistics; and how to evaluate them for reliability.
Download or read book Blood Medicine written by Kathleen Sharp and published by Penguin. This book was released on 2012-08-28 with total page 450 pages. Available in PDF, EPUB and Kindle. Book excerpt: “Blood Feud rivals A Civil Action for best non-fiction book of the past twenty years.” — John Lescroart, New York Times bestselling author of Damage Procrit seemed like a biotech miracle, promising a golden age in medical care. Developed in the 1980s by Amgen and licensed to the pharmaceutical giant, Johnson & Johnson, the drug (AKA Epogen and Aranesp) soon generated billions in annual revenue—and still does. In 2012, world famous cyclist, Olympian, and Tour de France champion Lance Armstrong was banned from professional cycling on doping charges for using EPO (the blanket name for the drugs Procrit and Epogen), resulting in a global controversy about abuse, big pharmaceutical companies, and the lies and inaccuracies concerning performance-enhancing drugs. Mark Duxbury was a J&J salesman who once believed in the blood-booster, setting record sales and winning company awards. Then Duxbury started to learn unsavory truths about Procrit and J&J’s business practices. He was fired and filed a whistleblower suit to warn the public. When Jan Schlichtman (A Civil Action) learned of Duxbury’s crusade, he signed on. Now, he’s fighting on behalf of cancer patients and for every American who trusts Big Pharma with his life.
Download or read book Patents on Biotechnological Processes and to Authorize Use by Regulation the Representation of Woodsy Owl written by United States. Congress. House. Committee on the Judiciary. Subcommittee on Courts and Intellectual Property and published by . This book was released on 1995 with total page 88 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Pharmaceutical R D written by and published by DIANE Publishing. This book was released on 1993 with total page 380 pages. Available in PDF, EPUB and Kindle. Book excerpt: Analyzes the costs, risks, and economic rewards of pharmaceutical R&D and the impact of public policy on both costs and returns. Examines the rapid increase in pharmaceutical R&D that began in the 1980s in the light of trends in science, technology, drug discovery, and health insurance coverage; Government regulation; product liability; market competition; Federal tax policy; and Federal support of prescription drug research. 12 appendices, including a glossary of terms.
Download or read book Mosby s Oncology Nursing Advisor E Book written by Susan Newton and published by Elsevier Health Sciences. This book was released on 2016-09-10 with total page 528 pages. Available in PDF, EPUB and Kindle. Book excerpt: Get quick access to the most important information surrounding cancer and oncology nursing care with Mosby’s Oncology Nursing Advisor, 2nd Edition. Covering everything from the various types of cancer and cancer treatment options to patient education and nursing best-practices, this indispensable nursing guide is like getting seven books in one! Plus, its user-friendly layout and straightforward coverage make it ideal for use in any clinical setting. With 17 new chapters, updated evidence-based content throughout, and proven patient teaching handouts, this new edition offers the authoritative guidance you need to provide the best possible oncology nursing care. Detailed descriptions of over 50 major cancer types provide essential information on incidence, etiology and risk factors, signs and symptoms, diagnostic workup, histology, staging, treatment, prognosis, and prevention. Coverage of cancer management principles outlines a wide range of treatment and pharmacologic modalities, including surgery, chemotherapy, radiation therapy, hormonal therapy, immunotherapy, and complementary and alternative therapies. Symptom management guidelines offer in-depth coverage of pathophysiology, signs and symptoms, assessment tools, lab and diagnostic tests, differential diagnoses, interventions, patient education, follow up care, and resources for over 30 common symptoms associated with cancer and cancer treatments. Essential information on many oncologic emergencies and emergent issues prepares readers to respond quickly to structural, metabolic, and hematologic emergencies. Section on palliative care and end-of-life issues offers helpful guidelines for dealing with topics related to survivorship, palliative care, the final hours of the cancer patient, and loss, grief, and bereavement. NEW! Updated evidence-based content reflects the latest national and international quality standards regarding various cancer types, major drug and non-drug treatments, treatment protocols, and approaches to symptom management. NEW! Nursing Practice Considerations section incorporates information on communication, cultural considerations, ethical considerations, safe and quality care, evidence-based practice, patient navigation, and patient education. NEW! 17 new chapters cover topics including myelofibrosis, neuroendocrine cancers, tumor treating fields, oral adherence, clinical trials, epistaxis, hypersensitivity reactions, hypertension, hyperglycemia, nail changes, ocular and visual changes, rashes, survivorship, quality and safety, evidence-based practice, nurse navigation, and patient education. NEW! Expanded content on patient education keeps readers on top of best practices in this critical area. NEW! High-quality electronic patient teaching handouts are evidence-based and have been vetted by practicing nurses.
